Martine Zimmermann - 22 Sep 2023 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
By: /s/ Andrew Reardon For: Martine Zimmermann
Issuer symbol
LGND
Transactions as of
22 Sep 2023
Net transactions value
$0
Form type
4
Filing time
26 Sep 2023, 16:41:12 UTC
Next filing
18 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Award $0 +2,285 $0.000000 2,285 22 Sep 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Employee Stock Option (right to buy) Award $0 +11,345 $0.000000 11,345 22 Sep 2023 Common Stock 11,345 $59.08 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on September 22, 2024; September 22, 2025; and September 22, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
F2 Grant of Stock Options that will vest and become exercisable in three substantially equal annual installments on September 22, 2024; September 22, 2025; and September 22, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date.